A Phase 2 interventional study of Adempas in Chronic Thromboembolic Disease (CTED) and Exercise Intolerance Post PEA Surgery, sponsored by University of Colorado, Denver. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by University of Colorado, Denver · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open label study of Riociguat in patients with continued exercise intolerance at least 6 months following pulmonary endarterectomy (PEA).
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Riociguat (Adempas) 0.5mg to 2.5 mg three time daily - oral medication
Drug: Adempas
After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.
Also known as: Riociguat
Change in mean pulmonary arterial pressure
Measurements include mPAP (mean pulmonary arterial pressure) measured by right heart catheterization (RHC)
Time frame: Baseline and 3 months
Change in cardiac output
Measurements include CO (cardiac output) mPAP/CO slope measured by right heart catheterization (RHC)
Time frame: Baseline and 3 months
Change in Pulmonary artery compliance
Measurements include Pulmonary artery compliance measured by right heart catheterization (RHC)
Time frame: Baseline and 3 months
Change in 6 minute walk test
Measurements include change in 6 minute walk test (6 MWT) following 3 months of study drug
Time frame: Baseline and 3 months
Change in New York Heart Association (NYHA) functional class
Measurements include Change in New York Heart Association (NYHA) functional class following 3 months of study drug
Time frame: Baseline and 3 months
Change in the University of California San Diego (UCSD) shortness of Breath Score
Measurements include: Change in the University of California San Diego (UCSD) shortness of Breath Score following 3 months of study drug
Time frame: Baseline and 3 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2018 to primary completion in Jan 2026, 91 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Riociguat
University of Colorado, Denver →